Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec;20(4):767-777.
doi: 10.1111/vco.12848. Epub 2022 Jul 20.

Blood biomarkers for canine cancer, from human to veterinary oncology

Philippe Colombe  1   2 , Jérémy Béguin  2   3 , Ghita Benchekroun  2   4 , Delphine Le Roux  1   5
Affiliations
Review

Blood biomarkers for canine cancer, from human to veterinary oncology

Philippe Colombe et al. Vet Comp Oncol. 2022 Dec.

Abstract

In recent decades, interest in circulating tumour biomarkers is increasing both in human and veterinary oncology. An ideal tumour biomarker would allow early diagnosis of neoplasia, identify it specifically, accurately, establish a prognosis and predict its behaviour, especially regarding different therapeutic solutions. It would also allow to monitor its evolution over time and all this in a non-invasive and inexpensive way. Actually, no biomarkers meeting all of these criteria have been identified in veterinary medicine, particularly due to a lack of specificity of the main protein tumour biomarkers studied to date. However, great hope is currently placed in biomarkers grouped under the name of liquid biopsy, which could prove to be effective tools for common clinical use in the near future. This review gives an update on blood cancer biomarkers studied in dogs, such as ions, proteins, nucleic acids and also circulating cells, of which some might become more prominent in the coming years to help improve the management of animal care.

Keywords: biomarker; cancer; liquid biopsy; veterinary.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest to declare.

References

    1. Henry NL, Hayes DF. Cancer biomarkers. Mol Oncol. 2012;6(2):140‐146. - PMC - PubMed
    1. Febbo PG, Ladanyi M, Aldape KD, et al. NCCN task force report: evaluating the clinical utility of tumor markers in oncology. J Natl Compr Cancer Netw. 2011;9(Suppl 5):S1‐S32. quiz S33. - PubMed
    1. Brady DC, Crowe MS, Turski ML, et al. Copper is required for oncogenic BRAF signalling and tumorigenesis. Nature. 2014;509(7501):492‐496. - PMC - PubMed
    1. Pan Q, Kleer CG, van Golen KL, et al. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res. 2002;62(17):4854‐4859. - PubMed
    1. MacDonald G, Nalvarte I, Smirnova T, et al. Memo is a copper‐dependent redox protein with an essential role in migration and metastasis. Sci Signal. 2014;7(329):ra56. - PubMed

Substances